- Conditions
- Advanced Solid Malignancies
- Interventions
- CT7001, Fulvestrant
- Drug
- Lead sponsor
- Carrick Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Beverly Hills, California • Tampa, Florida + 9 more
Therapy Directory
Fulvestrant clinical trials
Directory of U.S. ClinicalTrials.gov public records that list Fulvestrant as a study intervention. Browse Fulvestrant recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
294
Shown on this page
12
Current sort
Recently updated
Therapy scope
Fulvestrant
Additional filters apply within this therapy.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 97–108 of 294 matching trials for Fulvestrant.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Metastatic Breast Cancer
- Interventions
- Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
- Drug
- Lead sponsor
- LeonaBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 36
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Santa Rosa, California + 25 more
- Conditions
- Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
- Interventions
- EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant, Exemestane
- Drug
- Lead sponsor
- Ellipses Pharma
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 4 more
- Conditions
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Interventions
- Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 55
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more
- Conditions
- ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
- Interventions
- IDE574, Fulvestrant injection
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Plantation, Florida • East Brunswick, New Jersey • Lake Success, New York + 7 more
- Conditions
- Low Grade Ovarian Serous Adenocarcinoma
- Interventions
- nab-Sirolimus, Fulvestrant
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Metastatic Breast Cancer
- Interventions
- Palbociclib, Fulvestrant
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 2 more
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- fulvestrant, anastrozole
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 856
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 524 more
- Conditions
- Breast Cancer, Quality of Life
- Interventions
- Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
- Radiation · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2027
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Lowell, Massachusetts • South Weymouth, Massachusetts
- Conditions
- Advanced Breast Cancer
- Interventions
- Lerociclib + Letrozole or Fulvestrant
- Drug
- Lead sponsor
- EQRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Omaha, Nebraska • Salem, Oregon + 3 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Positive Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Carboplatin, Docetaxel, Fulvestrant, Pertuzumab, Quality-of-Life Assessment, Ribociclib, Trastuzumab, Tucatinib
- Drug · Biological · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
About this Fulvestrant clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Fulvestrant as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
- How to narrow results
- Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Fulvestrant.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Fulvestrant.